siRNA treatment reduces triglycerides in individuals with uncommon condition

.RESEARCH STUDY HIGHLIGHT.19 September 2024.

Plozasiran reduced triglyceride degrees through 80% and also decreased the risk of pancreatitis in people with constant chylomicronemia, with or without a hereditary prognosis.